1 hour ago
1
Skip to navigation Skip to main contented Skip to close file
TipRanks
Thu, April 9, 2026 astatine 7:39 AM CDT 1 min read
Truist lowered the firm’s price target connected BeOne Medicines (ONC) to $411 from $412 and keeps a Buy standing connected the shares arsenic portion of a broader probe enactment previewing Q1 net successful Biotech. Reactivity to regulatory and argumentation shifts crossed the assemblage continues to ease, and the steadfast besides notes a caller pickup successful woody activity, which has the imaginable to physique momentum done the remainder of the twelvemonth into mid-terms, the expert tells investors successful a probe note. For the company, the steadfast expect commentary to absorption connected the FY26 guidance and its imaginable update arsenic good arsenic Brukinsa’s outlook amidst the competitory dynamics from Calquence’s AMPLIFY and Jaypirca, Truist added.
-
Unlock hedge fund-level information and almighty investing tools for smarter, sharper decisions
-
Discover top-performing banal ideas and upgrade to a portfolio of marketplace leaders with Smart Investor Picks
Published archetypal connected TheFly – the eventual root for real-time, market-moving breaking fiscal news. Try Now>>
See the apical stocks recommended by analysts >>
Read More connected ONC:
Disclaimer & DisclosureReport an Issue
-
Buy Rating connected BeOne Medicines: Strong Brukinsa Positioning, Deep Oncology Pipeline, and Attractive Valuation Ahead of 2026 Milestones
-
BeOne Medicines initiated with an Outperform astatine Wolfe Research
-
BeOne Medicines Advances Combo Cancer Pill With Completed Phase 1 Bioavailability Study
-
BeOne Medicines attraction of hepatocellular carcinoma granted orphan designation
-
BeOne Medicines Advances BG-A3004 Into First-in-Human Skin Disease Trial: What Investors Should Watch
English (CA) · 
English (US) · 
Spanish (MX) ·